PHOTODYNAMIC THERAPY WITH PHOTODYTAZIN IN THE TREATMENT OF THE MIDDLE CHOROIDAL MELANOMAS

The Z rst clinical experience of transpupillary photodynamic therapy (PDT) with chlorine photosensitizer (PS) Photodytazin for middle choroidal melanoma is presented. PS, 0,8 mg/kg, was infused intravenously fractionally: 2 hours (70 % dose during 20 minutes) and 15 minutes (30 % dose during 10 minutes) before PDT. PDT was controlled by ˆ uorescent diagnosis with Photodytazin. Transpupillary laser irradiation was per- formed delay 2 hours after the Z rst PS infusion. Laser irradiation was carried out by spots 4,5 mm in diameter, concentrically, from periphery to the center of the tumor. Next spots recovered each other by 10 - 15 %. Laser ˆ uence in one spot was 50 J/cm 2 when the tumor periphery was irradiating, and 100 J/cm 2 — on the tumor apex. Total number of the spots was 8. Almost complete tumor regression with residual prominence of Z brous scar in the irradiated tumor site was found delay 6 months after PDT. B-scan showed decrease of the tumor basis and prominence from 8,5 6,6 mm to 7,2 5,0 and from 3,4 to 1,0 mm, accordingly. Color doppler imaging showed an absence of the tumor blood ˆ ow. Final visual acuity was 0,4. We suggest that transpupillary PDT might be the effective and functional-saving technique for the treatment of patients with the small and middle choroidal melanoma.